## Julien Riou

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4219305/publications.pdf

Version: 2024-02-01

		8	840776	580821	
28	2,114		11	25	
papers	citations		h-index	g-index	
36	36		36	4152	
all docs	docs citations		times ranked	citing authors	

#	Article	IF	CITATIONS
1	Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Eurosurveillance, 2020, 25, .	7.0	1,057
2	Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. Lancet, The, 2013, 382, 694-699.	13.7	342
3	Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: A modeling study in Hubei, China, and six regions in Europe. PLoS Medicine, 2020, 17, e1003189.	8.4	120
4	Early evidence of effectiveness of digital contact tracing for SARS-CoV-2 in Switzerland. Swiss Medical Weekly, 2020, 150, w20457.	1.6	114
5	Socioeconomic position and the COVID-19 care cascade from testing to mortality in Switzerland: a population-based analysis. Lancet Public Health, The, 2021, 6, e683-e691.	10.0	85
6	Regional excess mortality during the 2020 COVID-19 pandemic in five European countries. Nature Communications, 2022, 13, 482.	12.8	67
7	A comparative analysis of Chikungunya and Zika transmission. Epidemics, 2017, 19, 43-52.	3.0	34
8	An introduction to the partial least squares approach to structural equation modelling: a method for exploratory psychiatric research. International Journal of Methods in Psychiatric Research, 2016, 25, 220-231.	2.1	29
9	Bayesian workflow for disease transmission modeling in Stan. Statistics in Medicine, 2021, 40, 6209-6234.	1.6	26
10	Is There Still a French Eating Model? A Taxonomy of Eating Behaviors in Adults Living in the Paris Metropolitan Area in 2010. PLoS ONE, 2015, 10, e0119161.	2.5	24
11	Historically High Excess Mortality During the COVID-19 Pandemic in Switzerland, Sweden, and Spain. Annals of Internal Medicine, 2022, 175, 523-532.	3.9	18
12	Estimating the cumulative incidence of SARS-CoV-2 with imperfect serological tests: Exploiting cutoff-free approaches. PLoS Computational Biology, 2021, 17, e1008728.	3.2	16
13	Accounting for uncertainty during a pandemic. Patterns, 2021, 2, 100310.	5.9	13
14	Bridging the gap between HIV epidemiology and antiretroviral resistance evolution: Modelling the spread of resistance in South Africa. PLoS Computational Biology, 2019, 15, e1007083.	3.2	11
15	Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak. PLoS Neglected Tropical Diseases, 2019, 13, e0007978.	3.0	9
16	Drivers of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in nine southern African countries: a modelling study. BMC Infectious Diseases, 2021, 21, 1042.	2.9	7
17	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. PLoS Medicine, 2020, 17, e1003397.	8.4	7
18	Survival among people hospitalized with COVID-19 in Switzerland: a nationwide population-based analysis. BMC Medicine, 2022, 20, 164.	5.5	6

#	Article	IF	CITATIONS
19	Estimating Tuberculosis Transmission Risks in a Primary Care Clinic in South Africa: Modeling of Environmental and Clinical Data. Journal of Infectious Diseases, 2022, 225, 1642-1652.	4.0	5
20	Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis. Journal of Clinical Epidemiology, 2022, 148, 135-145.	5.0	5
21	Improving early epidemiological assessment of emerging Aedes-transmitted epidemics using historical data. PLoS Neglected Tropical Diseases, 2018, 12, e0006526.	3.0	4
22	Novel approach to estimate tuberculosis transmission in primary care clinics in sub-Saharan Africa: protocol of a prospective study. BMJ Open, 2020, 10, e036214.	1.9	4
23	Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxis. Nature Communications, 2021, 12, 1219.	12.8	2
24	A mechanistic model for long-term immunological outcomes in South African HIV-infected children and adults receiving ART. ELife, 2021, 10, .	6.0	1
25	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
26	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
27	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
28	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0